Eli Lilly and Company (LLY) — closed signal from March 31, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 29, 2026.
Predicted vs. what happened
LLY price · publication thesis → realized outcomesplit-adjusted
$895.00 – $920.00Entry zone — fair-value band
$911.02Published — price the day we called it
$1,056.78Target — the price the thesis aimed for
$1,238.00Peak — highest point inside the window, not a realized return
$1,229.93Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 52 days.
Peak price
$1,238.00
peak on June 29, 2026 — not a realized returnPeak gain
+35.9%
peak, from the publication priceWindow close
$1,229.93
end-of-window price, context onlyDays to target
52
Window
March 31, 2026 – June 29, 2026
The thesis — published March 31, 2026
Predicted growth
+16%
over the measurement windowTarget price
$1,056.78
the price the thesis aimed forEntry zone
$895.00 – $920.00
the fair-value band we waited forPrice at publication
$911.02
published March 31, 2026Confidence
81%
how strongly the data lined upTimeframe
Short-term (0–3 months)
LLY is a defensive growth pick for the next few months because recent deals keep its drug pipeline in focus while established medicines provide steady sales. The stock fell a bit, which makes the price range more workable. If investors favor steady earnings and health-sector leadership again, the stock is positioned to recover.
Primary drivers
- Obesity and flagship drugs keep revenue stable and reliable
- Centessa deal adds new drug programs and future upside
- Insilico tie-up brings faster, tech-driven drug discovery potential
- The recent price drop creates a calmer, more balanced setup
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.